BioScrip Agrees To Pay $15M In FCA Kickback Suit

By Jeff Sistrunk · January 8, 2014, 6:52 PM EST

BioScrip Inc. has agreed to pay $15 million to exit a False Claims Act whistleblower suit alleging it received kickbacks from Novartis Pharmaceuticals Corp. to push patients to continue using Novartis'...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

United States of America, ex rel, et al v. Novartis Pharmaceuticals Corporation

Case Number

Court

New York Southern

Nature of Suit

Other Statutes: False Claims Act

Date Filed

November 14, 2011

Recent Articles By Jeff

April 14, 2021
8th Circ. Skeptical Of Dental Clinic's COVID-19 Coverage Bid
April 13, 2021
A Guide To The 1st Appellate Clash Over COVID-19 Coverage
March 12, 2021
Nev. Justices Say Insurer Can Recoup Costs From Implant Co.
January 15, 2021
Insurer Asks 8th Circ. To Affirm Win In Virus Coverage Bout
November 19, 2020
Lawmakers Probe Reinsurance Plan For Future Pandemics
August 20, 2020
3rd Circ. Upholds Liberty's Win In Pharmacy's Painkiller Suit
August 06, 2020
Hiscox Defeats Health Co.'s Bid For HHS Subpoena Coverage
August 04, 2020
7th Circ. Told Chubb Unit Must Cover Lab's $3.3M TCPA Deal
July 30, 2020
JPML Questions If One Size Fits All For Virus Cases
June 11, 2020
Hiscox Must Fund NY Drug Biz's Defense In Opioid Trial